Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. Its products include A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, ,Candaderm, Coco-Scalp, Cromo-Fresh, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE, Itch-Soothe, Kiwisoothe, Lax-Tab, Loraclear, VitA-POS, and others.
- Revenue in NZD (TTM)195.41m
- Net income in NZD15.61m
- Incorporated1997
- Employees110.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttp://www.aftpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SinoMab Bioscience Ltd | 479.65k | -47.26m | 269.19m | 214.00 | -- | 4.11 | -- | 561.21 | -0.2061 | -0.2061 | 0.0021 | 0.2728 | 0.0023 | -- | -- | 10,133.96 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Fuso Pharmaceutical Industries Ltd | 639.17m | 24.31m | 278.38m | 1.31k | 10.33 | 0.5996 | 5.61 | 0.4355 | 257.39 | 257.39 | 6,774.96 | 4,436.49 | 0.7581 | 3.07 | 2.33 | 44,163,730.00 | 2.89 | 1.91 | 4.97 | 3.09 | 26.58 | 26.92 | 3.81 | 2.69 | 0.9406 | 50.75 | 0.267 | 41.10 | 8.61 | 3.76 | -14.21 | 9.02 | 9.13 | -2.64 |
| Bliss GVS Pharma Ltd | 162.41m | 12.87m | 281.24m | 831.00 | 22.14 | 1.37 | 13.91 | 1.73 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Remus Pharmaceuticals Ltd | 43.13m | 4.37m | 282.22m | 48.00 | 63.21 | 16.01 | 51.74 | 6.54 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| AFT Pharmaceuticals Ltd | 195.41m | 15.61m | 284.19m | 110.00 | 18.21 | 3.24 | 16.13 | 1.45 | 0.1489 | 0.1489 | 1.86 | 0.8372 | 1.25 | 2.34 | 4.30 | 1,776,464.00 | 9.96 | 11.44 | 13.72 | 16.49 | 45.17 | 45.65 | 7.99 | 9.50 | 1.23 | 6.69 | 0.2683 | 4.43 | 24.75 | 18.08 | 46.51 | -- | 22.42 | -- |
| Jbm (Healthcare) Ltd | 158.62m | 36.08m | 285.92m | 279.00 | 8.08 | 1.30 | 5.95 | 1.80 | 0.1955 | 0.1955 | 0.8564 | 1.22 | 0.5069 | 4.64 | 4.38 | 2,582,581.00 | 12.10 | 4.38 | 15.12 | 5.52 | 51.75 | 46.47 | 23.86 | 12.69 | 1.27 | 54.59 | 0.0768 | 32.98 | 24.62 | 16.09 | 128.51 | 19.99 | 2.26 | -- |
| Hyloris Pharmaceuticals SA | 9.07m | -21.84m | 286.93m | 24.00 | -- | 4.64 | -- | 31.64 | -0.4281 | -0.4281 | 0.1789 | 1.24 | 0.0989 | -- | 1.19 | -- | -23.82 | -22.79 | -28.07 | -28.09 | 96.95 | 92.05 | -240.77 | -815.53 | -- | -- | 0.0516 | -- | 131.89 | 87.11 | -29.18 | -- | 89.12 | -- |
| Scpharmaceuticals Inc | 51.89m | -137.29m | 287.20m | 135.00 | -- | 5.46 | -- | 5.54 | -1.91 | -1.91 | 0.7417 | 0.6137 | 0.262 | 0.7268 | 4.52 | 224,281.50 | -69.31 | -38.23 | -78.18 | -42.31 | 69.72 | -- | -264.60 | -1,360.16 | 6.89 | -8.42 | 0.6246 | -- | -- | -- | -48.79 | -- | -- | -- |
| Sinphar Pharmaceutical Co Ltd | 160.17m | 17.51m | 296.82m | 984.00 | 16.98 | 1.77 | 9.86 | 1.85 | 1.83 | 1.83 | 16.78 | 17.56 | 0.4901 | 2.34 | 6.85 | -- | 5.29 | -0.0147 | 6.91 | -0.0203 | 38.51 | 37.49 | 10.80 | -0.0344 | 1.58 | 19.25 | 0.3435 | 79.70 | 3.72 | 5.98 | 67.01 | 111.88 | 3.31 | 60.95 |
| Cenra Inc | 470.05m | 19.56m | 297.14m | 1.40k | 25.34 | 0.754 | 7.81 | 0.6322 | 1.50 | 1.50 | 34.28 | 50.26 | 0.7106 | 2.15 | 5.73 | -- | 2.97 | 3.69 | 4.29 | 4.96 | 37.10 | 36.56 | 4.18 | 5.50 | 0.7054 | -- | 0.2976 | 52.77 | 1.40 | 2.50 | -32.51 | -2.72 | 3.57 | -8.97 |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 06 Nov 2024 | 7.52m | 7.17% |
| Guardians of New Zealand Superannuationas of 30 Apr 2024 | 1.70m | 1.62% |
| Salt Funds Management Ltd.as of 30 Apr 2024 | 319.83k | 0.31% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 73.45k | 0.07% |
| FCA Corp.as of 30 Sep 2024 | 46.00k | 0.04% |
